NextCell Pharma AB (STO:NXTCL)

NextCell Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022
Operating Revenue	9.62	10.94	10.66	10.11	5.59
Other Revenue	0.21	0.13	0.61	3.84	0.64
Revenue	9.83	11.06	11.28	13.96	6.23
Revenue Growth (YoY)	-11.13%	-1.90%	-19.18%	124.03%	39.82%
Cost of Revenue	8.18	9.4	15.22	11	8.72
Gross Profit	1.66	1.67	-3.94	2.96	-2.49
Selling, General & Admin	38.66	34.9	38.22	43.47	31.85
Other Operating Expenses	-0.04	0.14	0.04	0.04	0.22
Operating Expenses	41.11	37.55	39.23	43.96	32.53
Operating Income	-39.46	-35.89	-43.17	-41	-35.02
Interest Expense	-0	-0	-0	-0	-0.01
Interest & Investment Income	0.67	0.75	1.21	1.19	0.48
Pretax Income	-38.79	-35.14	-41.96	-39.81	-34.55
Net Income	-38.79	-35.14	-41.96	-39.81	-34.55
Net Income to Common	-38.79	-35.14	-41.96	-39.81	-34.55
Shares Outstanding (Basic)	-	76	41	34	34
Shares Outstanding (Diluted)	-	76	41	34	34
Shares Change (YoY)	-	87.22%	18.72%	-	13.05%
EPS (Basic)	-	-0.46	-1.03	-1.16	-1.01
EPS (Diluted)	-	-0.46	-1.03	-1.16	-1.01
Free Cash Flow	-46.57	-43.05	-37.86	-47.92	-40.9
Free Cash Flow Per Share	-	-0.56	-0.93	-1.39	-1.19
Gross Margin	16.84%	15.07%	-34.98%	21.19%	-40.03%
Operating Margin	-401.24%	-324.35%	-382.79%	-293.81%	-562.26%
Profit Margin	-394.49%	-317.62%	-372.04%	-285.28%	-554.72%
Free Cash Flow Margin	-473.62%	-389.04%	-335.70%	-343.41%	-656.63%
EBITDA	-36.96	-33.37	-42.2	-40.55	-34.57
EBITDA Margin	-	-	-	-290.60%	-
D&A For EBITDA	2.49	2.52	0.97	0.45	0.46
EBIT	-39.46	-35.89	-43.17	-41	-35.02
EBIT Margin	-	-	-	-293.81%	-
Revenue as Reported	9.83	11.06	11.28	13.96	6.23

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.